Stevanato Group expands drug delivery system manufacturing capacity

Stevanato Group (STVN) announced an expansion of its drug delivery system manufacturing capacity. As part of its footprint optimization plan, the company recently added a state-of-the-art production space for drug delivery devices to its facility in Bad Oeynhausen, northern Germany. This initiative provides more than 2,500 square meters of manufacturing capacity designed to serve global pharma and biotech partners seeking robust and resilient European supply-chain integration. The multi-million investment includes installation of an ISO 8 cleanroom environment, fully equipped for injection molding and automated assembly operations. These upgrades enable the site to support both Stevanato Group’s proprietary device production and contract manufacturing services enhancing operational flexibility, scalability, and speed-to-market across the company’s drug delivery systems portfolio.